CD markers variations in chronic lymphocytic leukemia: New insights into prognosis.
Antigens, CD
/ genetics
Apoptosis
/ genetics
B-Lymphocytes
/ metabolism
Biomarkers, Tumor
/ genetics
Clonal Evolution
/ genetics
Gene Expression Regulation, Leukemic
/ genetics
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
/ genetics
Lymphocytes
/ metabolism
Prognosis
Tumor Microenvironment
/ genetics
CD markers
chronic lymphocytic leukemia
prognosis
Journal
Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
24
01
2019
revised:
31
03
2019
accepted:
11
04
2019
pubmed:
3
5
2019
medline:
30
5
2020
entrez:
4
5
2019
Statut:
ppublish
Résumé
Chronic lymphocytic leukemia (CLL) is one of the most commonly occurring adult leukemias that is associated with clonal accumulation of mature apoptosis-resistant B-cells in bone marrow, peripheral blood, and specific tissues. Different pathogenesis factors can contribute to the aggression of the clinical course in this disease. Cytogenetic abnormalities and surface biomarkers of neoplastic CLL cells can be effective in the outcome of CLL, and the examination of changing CD markers expressions in the progression of CLL can be related to the prognosis of this disease. Changing expression levels of CD markers on lymphocytes and other cells in CLL patients can play a role in the aggressive clinical outcomes such as organomegaly, immunodeficiency, and advanced disease stages through their interaction with CLL microenvironment. Given the involvement of CD markers in the pathogenesis of CLL, it can be stated that recognizing the expression changes of CD markers in the cells involved in CLL can be a proper approach to evaluate prognosis among these patients.
Substances chimiques
Antigens, CD
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
19420-19439Informations de copyright
© 2019 Wiley Periodicals, Inc.